We are live on ! Find out more
AMBI

Ambit Biosciences Corp
AMBI

Delisted

AMBI was delisted on the 10th of November, 2014.

Back to rankings

35 hedge funds and large institutions have $79.3M invested in Ambit Biosciences Corp in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

52% more funds holding

Funds holding: 23 → 35 (+12)

4% more capital invested

Capital invested by funds: $76M → $79.3M (+$3.37M)

Holders
35
Holders Change
+12
Holders Change %
+52.17%
% of All Funds
1.02%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
17
Increased
10
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$7.29M
2
AG
Artal Group
Luxembourg
+$3.34M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.55M
4
BIT
BlackRock Institutional Trust
California
+$1.14M
5
SM
Sabby Management
Florida
+$868K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$2.01M
2
Millennium Management
Millennium Management
New York
-$1.56M
3
EI
EAM Investors
California
-$1.54M
4
WC
Wexford Capital
Florida
-$900K
5
FM
Forward Management
California
-$177K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management I
California
$20M +$27.8M +2,079,569 New
O
2
OrbiMed
New York
$14.4M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$8.86M +$1.55M +116,434 +15%
BBA
4
Baker Bros. Advisors
New York
$7.21M -$107 -8 -0%
GPP
5
Great Point Partners
Connecticut
$7.06M -$2.01M -150,859 -17%
RG
6
Redmile Group
California
$5.26M +$7.29M +545,985 New
WC
7
Wexford Capital
Florida
$5.12M -$900K -67,439 -11%
AG
8
Artal Group
Luxembourg
$2.41M +$3.34M +250,000 New
SFM
9
Sphera Funds Management
Israel
$2.26M +$3.12M +233,995 New
BIT
10
BlackRock Institutional Trust
California
$912K +$1.14M +85,146 +897%
Morgan Stanley
11
Morgan Stanley
New York
$794K +$671K +50,236 +156%
EAM
12
Eventide Asset Management
Massachusetts
$714K +$989K +74,100 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$713K +$467K +34,973 +90%
SM
14
Sabby Management
Florida
$627K +$868K +65,000 New
DCM
15
Driehaus Capital Management
Illinois
$579K +$801K +60,000 New
NI
16
Numeric Investors
Massachusetts
$369K +$511K +38,303 New
B
17
Bailard
California
$337K +$467K +35,000 New
HCM
18
Highbridge Capital Management
New York
$268K +$370K +27,738 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$260K +$15.7K +1,175 +5%
SIM
20
Spark Investment Management
New York
$222K -$12K -900 -4%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$209K +$122K +9,100 +72%
Northern Trust
22
Northern Trust
Illinois
$175K +$43.3K +3,240 +22%
BA
23
BlackRock Advisors
Delaware
$170K +$219K +16,416 +1,399%
BFA
24
BlackRock Fund Advisors
California
$168K +$233K +17,424 New
Macquarie Group
25
Macquarie Group
Australia
$147K +$203K +15,200 New
1
2

AMBI Hedge Fund Activity: Q4 2013 in Review

35 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q4 2013, worth a combined $79.3M — up 4.4% from $76M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new AMBI positions and 5 closed out — a net gain of 12 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $7.29M. The largest seller was Great Point Partners, cutting an estimated $2.01M.

  • 35 institutional investors held Ambit Biosciences Corp (AMBI) as of Q4 2013, up from 23 in Q3 2013.
  • Funds reported $79.3M of Ambit Biosciences Corp stock for Q4 2013, up 4.4% quarter-over-quarter.
  • 17 funds opened new Ambit Biosciences Corp positions in Q4 2013 and 5 closed out, a net change of +12 holders.
  • The largest Ambit Biosciences Corp buyer in Q4 2013 was Redmile Group, an estimated $7.29M added.
  • The largest Ambit Biosciences Corp seller in Q4 2013 was Great Point Partners, an estimated $2.01M sold.

Based on aggregated 13F filings for Q4 2013.